https://www.selleckchem.com/pr....oducts/rimiducid-ap1
Neither overall survival (OS) nor CLAD-free survival was significantly different between recipients with and without DSAs (P = 0.26 and P = 0.17, respectively). However, both OS and CLAD-free survival were significantly lower in recipients with DSAs against HLA class II than in those without these antibodies 5-year OS 25.0% [95% confidence interval (CI) 0.9-66.5%] vs 72.1% (95% CI 63.8-78.9%), P = 0.030 and 5-year CLAD-free survival 26.7% (95% CI 1.0-68.6%) vs 73.7% (95% CI 66.5-79.5%), P = 0.002. Prognosis in recipients experi
Like
Comment
Share
